Everything below concerns Incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
=== Possible health risks === Some evidence suggests that T. molitor may pose a health risk, as humans and animals can consume the eggs and larvae of the beetle with grain-based food. Although they are usually either digested or are excreted with feces, sometimes, they are able to survive and live in the alimentary tract. The first cases of T. molitor larvae in human organs date back to the 19th century, where their presence was observed in the gastrointestinal tract, including the stomach and intestines. There were other cases, such as a reported ulcer infestation of T. molitor in an AIDS patient and a concerned urinary canthariasis in a ten-year-old boy in Iran in 2019, which was the last reported human case of canthariasis caused by T. molitor. However, there are very few reported cases of live larvae in animals, and there are no reports of gastrointestinal canthariasis in farm animals. A study analysing the results of patients in Poland for the presence of specific IgE antibodies to the mealworm was conducted prior to its widespread introduction as a food ingredient. Sensitisation to the mealworm was detected in 4.3% of the patients, with monosensitisation occurring rarely and affecting 0.7% of this group. It was determined that the presence of antibodies to the mealworm most often co-occurs with sensitization to other edible insects, such as the house cricket and the migratory locust, as well as to tropomyosins from shrimp and house dust mites. The primary or cross-sensitization may differ in different populations depending on the dietary habits or geographical zone.
=== In food === In 2004, the chemical was found in cow's milk in California at an average level of 1.3 parts per billion (ppb, or μg/L), which may have entered the cows through feeding on crops exposed to water containing perchlorates. A 2005 study suggested human breast milk had an average of 10.5 μg/L of perchlorate.
=== 17 October === The SAF and the RSF traded blame for a drone attack on a community meeting in Al-Mazroub, North Kordofan that killed 17 people, including Nazir Suleiman Jaber Juma’a Sahl, the leader of the Majaneen tribe. The JDF claimed to have retaken Abu Gamra. The SAF and allied forces claimed to have repelled an RSF attack on El Fasher, destroying 10 RSF vehicles and capturing two others.
Sources: en.wikipedia.org
Freeze-dried nanocellulose aerogels used in sanitary napkins, tampons, diapers or as wound dressing The use of nanocellulose as a composite coating agent in cosmetics e.g. for hair, eyelashes, eyebrows or nails A dry solid nanocellulose composition in the form of tablets for treating intestinal disorders Nanocellulose films for screening of biological compounds and nucleic acids encoding a biological compound Filter medium partly based on nanocellulose for leukocyte free blood transfusion A buccodental formulation, comprising nanocellulose and a polyhydroxylated organic compound Powdered nanocellulose has also been suggested as an excipient in pharmaceutical compositions Nanocellulose in compositions of a photoreactive noxious substance purging agent Elastic cryo-structured gels for potential biomedical and biotechnological application Matrix for 3D cell culture
=== Other components === Autonomy and freedom are often-discussed factors of well-being. They concern the possibility to choose, the ability to make informed decisions without coercion, and the capacity to act without being constrained by external forces. Individuals with a high level of autonomy and freedom tend to be more satisfied by having control over their lives. This enables them to decide between important options and choose a life that reflects their desires, preferences, and values. However, these conditions may not automatically lead to well-being and can sometimes have negative consequences. For example, a person lacking mental maturity and wisdom may freely engage in short-sighted pleasures with instant gratification while ignoring negative long-term consequences. Eudaimonic conceptions of well-being stress the importance of character traits and virtues. Character traits are stable and consistent aspects of personality that influence how people think, feel, and act. Traits associated with well-being include wisdom, courage, kindness, justice, temperance, and gratitude. Virtues are character traits that promote ethical excellence, such as dispositions to act morally and follow ethical principles. Virtue-based theories of well-being argue that virtue can be its own reward, for example, because living a morally upright life can be a fulfilling experience. However, virtue and well-being may also conflict in some cases, for instance, when altruistic service to a greater good requires personal sacrifice.
=== Inclusion of clothing and personal effects === The body may be dressed in fancy and/or ceremonial clothes. Personal objects of the deceased, such as a favorite piece of jewelry or photograph, may be included with the body. This practice, also known as the inclusion of grave goods, serves several purposes:
The device does not directly measure the blood sugar but rather tracks the interstitial glucose levels which are similar to blood glucose levels. The other part of the CGM, known as the transmitter, then sends the information to a receiver, an insulin pump, or a compatible smart device. Unlike the traditional glucose meter, CGMs will report the glucose level continuously and has an alarm that will alert the person if the glucose level is too high or low, helping to prevent emergencies. The device is able to graph the glucose readings over the time the sensor was in use and track trends. This allows for timely adjustment of diet, activity levels, medications, and/or illness. In addition, the information from the CGM can be downloaded and sent to a second person (such as a parent, caregiver, or partner) or physician for their review. CGMs have also been shown to improve glycemic control, reduce Hb A1c levels, and/or reduce the risk of hypoglycemic events. They also can reduce the need for multiple fingersticks throughout the day, which may be preferred by some individuals. Popular CGM devices include Dexcom, Freestyle Libre, and Medtronic. In addition to the above tests, glucose can be measured on routine labs. One common test ordered by healthcare providers is a Basic Metabolic Panel which is a blood test that looks at several different substances in the body, including blood glucose. Usually, individuals are told to fast for 8 hours before drawing the labs so that the provider can see the fasting glucose level.
Sources: en.wikipedia.org
=== Flammability === In the 1960s there was a lot of interest in fluorocarbons as anesthetics. The research did not produce any anesthetics, but the research included tests on the issue of flammability, and showed that the tested fluorocarbons were not flammable in air in any proportion, though most of the tests were in pure oxygen or pure nitrous oxide (gases of importance in anesthesiology).
Termination of elongation depends on the release factor eRF1 that recognizes all three stop codons. When a stop codon is reached, termination of the polypeptide occurs the ribosome is disassembled and the completed polypeptide is released. eRF3 is a ribosome-dependent GTPase that helps eRF1 release the completed polypeptide. The human genome encodes a few genes whose mRNA stop codons are surprisingly leaky: In these genes, termination of translation is inefficient due to special RNA bases in the vicinity of the stop codon. Leaky termination in these genes leads to translational readthrough of up to 10% of the stop codons of these genes. Some of these genes encode functional protein domains in their readthrough extension so that new protein isoforms can arise. This process has been termed 'functional translational readthrough'. When the A site of the ribosome is occupied by a stop codon (UAA, UAG, or UGA) on the mRNA, creating the primary structure of a protein. tRNA usually cannot recognize or bind to stop codons. Instead, the stop codon induces the binding of a release factor protein (RF1 & RF2) that prompts the disassembly of the entire ribosome/mRNA complex by the hydrolysis of the polypeptide chain from the peptidyl transferase center of the ribosome. Drugs or special sequence motifs on the mRNA can change the ribosomal structure so that near-cognate TRNAs are bound to the stop codon instead of the release factors. In such cases of 'translational readthrough', translation continues until the ribosome encounters the next stop codon.
Therians took over the medium- to large-sized ecological niches in the Cenozoic, after the Cretaceous–Paleogene extinction event approximately 66 million years ago emptied ecological space once filled by non-avian dinosaurs and other groups of reptiles, as well as various other mammal groups, and underwent an exponential increase in body size (megafauna). The increase in mammalian diversity was not, however, solely because of expansion into large-bodied niches. Mammals diversified very quickly, displaying an exponential rise in diversity. For example, the earliest-known bat dates from about 50 million years ago, only 16 million years after the extinction of the non-avian dinosaurs. Molecular phylogenetic studies initially suggested that most placental orders diverged about 100 to 85 million years ago and that modern families appeared in the period from the late Eocene through the Miocene. However, no placental fossils have been found from before the end of the Cretaceous. The earliest undisputed fossils of placentals come from the early Paleocene, after the extinction of the non-avian dinosaurs. (Scientists identified an early Paleocene animal named Protungulatum donnae as one of the first placental mammals, but it has since been reclassified as a non-placental eutherian.) Recalibrations of genetic and morphological diversity rates have suggested a Late Cretaceous origin for placentals, and a Paleocene origin for most modern clades. The earliest-known ancestor of primates is Archicebus achilles from around 55 million years ago.
CoviVac – COVID vaccine Cytestrol acetate – antiestrogen, cytostatic antineoplastic agent Deltaran (delta sleep-inducing peptide) – alcohol withdrawal treatment Dilept (GZR-123) – antipsychotic, neurotensin analogue Diucifon – leprostatic agent Emoxypine (Mexidol; Mexifin) – actoprotector, antioxidant EpiVacCorona – COVID vaccine Eprobemide (Befol) – antidepressant, reversible inhibitor of monoamine oxidase A Ethacizine (ethacyzine; Ethacizin) – antiarrhythmic agent Fabomotizole (Afobazole) – anxiolytic Feprosidnine (Sydnophen) – amphetamine derivative, psychostimulant Fluacizine (Phtorazisin) – tricyclic antidepressant, phenothiazine Fluorothiazinone (CL-55; Ftortiazinon) – investigational antibiotic Fotretamine (Fotrin) – alkylating antineoplastic agent, immunosuppressant Gamofen (gamophen; amphetamine–GABA) – amphetamine derivative, GABATooltip γ-aminobutyric acid analogue, central agent, central depressant Gidazepam (hydazepam, hidazepam) – atypical benzodiazepine, anxiolytic, TSPOTooltip translocator protein agonist/ligand Gludantan (gludantane) – adamantane, antiparkinsonian agent, antidepressant Glufimet (RGPU-238; dimethyl 3-phenylglutamate) – GABATooltip γ-aminobutyric acid and phenibut analogue Glutaron (RGPU-135; neuroglutamine, neuroglutam; β-phenylglutamate; 3-phenylglutamate) – glutamate analogue, psychostimulant, antidepressant, anxiolytic, neuroprotective Hemantane (hymantane) – adamantane, antiparkinsonian agent Hopantenic acid (homopantothenic acid; N-pantoyl-GABA; Pantogam) – central depressant, GABATooltip γ-aminobutyric acid analogue Ipidacrine (Neiromidin) – acetylcholinesterase inhibitor Latrepirdine (dimebolin; Dimebon) – antihistamine, antiserotonergic, nootropic Mecigestone (pentarane B) – progestin Megestrol caproate (MGC) – progestin Meldonium (Mildronate) – anti-ischemia agent Menthyl isovalerate (validolum; Extravalerianic, Validol, Valofin, Menthoval) – anxiolytic Mesocarb (Sidnocarb, Sydnocarb, Synocarb) – amphetamine derivative, psychostimulant Methylphenatine – amphetamine derivative, psychostimulant Methylphenylpiracetam – racetam, sigma σ1 receptor positive allosteric modulator α-Methyltryptamine (αMT; Indopan) – tryptamine derivative, antidepressant Metralindole (Inkazan) – antidepressant, reversible inhibitor of monoamine oxidase A Moracizine (moricizine; Ethmozine) – antiarrhythmic agent Nooglutyl (Nooglutil; N-5-hydroxynicotinoyl-L-glutamate) – nootropic Orenetide (BP101; Libicore; Desirix; Thr-Lys-Pro-Arg-Pro) – investigational small peptide, sexual enhancer Pabofen (pabophen; amphetamine–PABA) – amphetamine derivative, antihypoxic agent Pentarane A (D'6-pentarane) – progestin Phemerazole (femerazol; 5-phenyl-3-methylpyrazole) – sedative, hypnotic, anticonvulsant, muscle relaxant, mammary stimulant Phenatine (phenatin; Fenatine; amphetamine–niacin; N-nicotinoylamphetamine) – amphetamine derivative, psychostimulant, hypotensive agent Phenazepam – benzodiazepine, anxiolytic, sedative, hypnotic Phenibut (β-phenyl-GABA; Anvifen, Fenibut, Noofen; Citrocard, RGPU-147) – central depressant, anxiolytic, GABATooltip γ-aminobutyric acid analogue, gabapentinoid N-Phenylacetyl-L-prolylglycine ethyl ester (omberacetam; Noopept) – nootropic, racetam, cyclic glycine-proline prodrug Phenylphenamine (phenylamphetamine) – amphetamine derivative Phenylpiracetam (fonturacetam; Phenotropil, Actitropil, Carphedon) – psychostimulant, nootropic, racetam Phenylpiracetam hydrazide (fonturacetam hydrazide) – anticonvulsant, racetam Picamilon (N-nicotinoyl-GABA, pycamilon, and pikamilon) – anxiolytic, GABATooltip γ-aminobutyric acid analogue Pipofezine (Azafen, Azaphen) – tricyclic antidepressant Pirlindole (Lifril, Pyrazidol) – antidepressant, reversible inhibitor of monoamine oxidase A, serotonin–norepinephrine reuptake inhibitor Polymethylsiloxane polyhydrate (PMSPH; methylsilicic acid hydrogel; Enterosgel) – enterosorbent Propylphenamine (propylamphetamine; possibly N-propylamphetamine) – amphetamine derivative Prospidium chloride (prospidine) – cytostatic, anti-inflammatory agent Pyridoxiphen (amphetamine–pyridoxine; pyridoxylamphetamine) – amphetamine derivative, sympatholytic, hypotensive agent Quifenadine (Phencarol, Fencarol) – antihistamine RGPU-95 (p-chlorophenylpiracetam) – antidepressant, anxiolytic, racetam RGPU-207 (cyclic GABA derivative) – GABATooltip γ-aminobutyric acid analogue, mitochondrial modulator, racetam RGPU-260 – GABATooltip γ-aminobutyric acid analogue, cardiac stimulant Riamilovir (Triazavirin) – antiviral RU-1205 – analgesic, kappa opioid receptor agonist Selank – tuftsin analogue, nootropic, anxiolytic Semax – ACTHTooltip adrenocorticotropic hormone fragment analogue, nootropic, neuroprotective, neurorestorative Sodium polydihydroxyphenylene thiosulfonate (Hypoxen) – antihypoxic agent Sputnik Light – COVID vaccine Sputnik V – COVID vaccine Sulfozinum (sulfazin) – pyrogenic and pain-inducing agent used in psychiatry, for instance psychosis Temgicoluril (tetramethylglycoluril; Adaptol, Mebicar, Mebicarum, Mebikar) – anxiolytic Testifenon (testiphenon, testiphenone, chlorphenacyl dihydrotestosterone ester) – androgen/anabolic steroid, cytostatic antineoplastic agent Tetrindole – antidepressant, reversible inhibitor of monoamine oxidase A Thiophenatine (N-thionicotinoylamphetamine) – amphetamine derivative Tipindole – serotonin antagonist and monoamine oxidase inhibitor Tolibut (β-(4-methylphenyl)-GABA)) – anxiolytic, analgesic, neuroprotective, GABATooltip γ-aminobutyric acid and phenibut analogue Traneurocin (cycloprolylglycine; CPG; NA-831) – racetam-like neuroprotective, neurogenic, nootropic, and anxiolytic Trimeperidine – opioid analgesic Umifenovir (Arbidol) – antiviral Vishnevsky liniment – topical wound medication Phenamine (Fenamin), a psychostimulant, is not specifically a Russian drug but is rather the Russian name for amphetamine.
== External links == Antivenom Index, a joint project of the Association of Zoos and Aquariums and the American Association of Poison Control Centers which helps locate rare antivenoms Venom Response Program of the Miami-Dade Fire Rescue service
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.